RxDoctor Payments Data

Amir Naraghi, MD

Internal Medicine · Parma, OHNPI 1255752101

Payments from drug & device makers

$3,002in general payments, 2019–2025

Across 38 payments — averaging $79.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$912
  • Amgen$491
  • AbbVie$480
  • Angiodynamics, Inc.$345
  • Teva Pharmaceuticals USA, Inc.$250
  • AstraZeneca$138
  • plus $387 from 5 others

What the payments were for

  • Food & beverage$3,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,002 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$68,765
Medicare patients
229
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$18,996
TrulicityDulaglutide12$12,965
Spiriva RespimatTiotropium Bromide14$8,313
JanuviaSitagliptin Phosphate13$7,460
MyrbetriqMirabegron14$6,022
JardianceEmpagliflozin11$5,825
Divalproex Sodium108$5,135
Cimetidine26$2,357
Atorvastatin Calcium146$2,156
Esomeprazole Magnesium11$2,124
Paliperidone ErPaliperidone15$1,883
Sucralfate19$1,698
Humalog Kwikpen U-100Insulin Lispro31$1,597
LantusInsulin Glargine,hum.Rec.Anlog20$1,438
Buspirone Hcl57$1,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$77$12,96512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Parma

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →